advanced medical treatment – The Milli Chronicle

Thursday, October 9, 2025

Latest:

PepsiCo Sparkles with Strong Earnings and Fresh Leadership Amid Global Growth Momentum
Google Turns Cyber Threat into Triumph, Strengthens Global Digital Defenses Amid Oracle-Linked Hack
Elon Musk’s Visionary Tesla Deal Ignites Bold New Era for Innovation and AI Leadership
Novo Nordisk Makes Bold $5.2 Billion Move with Akero Buyout to Accelerate Liver Disease Breakthroughs
Wall Street’s Winning Streak: Investor Optimism Soars as U.S. Stock Options Reflect Renewed Market Confidence

Factual Version of a Story

Latest Middle East and North Africa News

NewsDesk Milli Chronicle October 9, 2025October 9, 2025 advanced medical treatment, ALS clinical outcomes, ALS drug registration, ALS medication Saudi Arabia, ALS treatment, amyotrophic lateral sclerosis, antisense therapy, clinical trials, Health Sector Transformation Program, innovative therapies, Kingdom healthcare development, nerve cell protection, neurodegenerative disease, neurofilament reduction, orphan drugs, patient access, pharmaceutical innovation, protein misfolding therapy, Qalsody approval, rare disease therapy, rare genetic disease treatment, Saudi Arabia healthcare, Saudi FDA, Saudi medical innovation, Saudi patient care, Saudi rare disease patients, SOD1 gene, SOD1 protein reduction., Tofersen, vision 2030

Saudi FDA Approves Qalsody for ALS, Pioneering New Hope for Rare Disease Patients

Riyadh – In a landmark decision for rare disease treatment in Saudi Arabia, the Saudi Food and Drug Authority (SFDA)